Morphine Attenuated the Cytotoxicity Induced by Arsenic Trioxide in H9c2 Cardiomyocytes.

Amini-Khoei, Hossein. and Hosseini, Mir-Jamal. and Momeny, Majid. and Rahimi-Balaei, Maryam. and Amiri, Shayan. and Haj-Mirzaian, Arya. and Khedri, Mostafa. and Jahanabadi, Samane. and Mohammadi-Asl, Ali. and Ejtemaie Mehr, Shahram. and Dehpour, Ahmad Reza. (2016) Morphine Attenuated the Cytotoxicity Induced by Arsenic Trioxide in H9c2 Cardiomyocytes. Biological trace element research, 173 (1).


Download (1MB) | Preview


Arsenic trioxide (ATO) is an efficient drug for the treatment of the patients with acute promyelocytic leukemia (APL). Inhibition of proliferation as well as apoptosis, attenuation of migration, and induction of differentiation in tumor cells are the main mechanisms through which ATO acts against APL. Despite advantages of ATO in treatment of some malignancies, certain harmful side effects, such as cardiotoxicity, have been reported. It has been well documented that morphine has antioxidant, anti-apoptotic, and cytoprotective properties and is able to attenuate cytotoxicity. Therefore, in this study, we aimed to investigate the protective effects of morphine against ATO toxicity in H9c2 myocytes using multi-parametric assay including thiazolyl blue tetrazolium bromide (MTT) assay, reactive oxygen species (ROS) generation, caspase 3 activity, nuclear factor kappa B (NF-κB) phosphorylation assay, and expression of apoptotic markers. Our results showed that morphine (1 μM) attenuated cytotoxicity induced by ATO in H9c2 cells. Results of this study suggest that morphine may have protective properties in management of cardiac toxicity in patients who receive ATO as an anti-cancer treatment.

Item Type: Article
Uncontrolled Keywords: Arsenic trioxide . Morphine . Cardiomyocyte . Cytotoxicity . H9c2
Subjects: QV pharmacology
QV pharmacology > QV 600 Toxicology
Divisions: Reserach Vice-Chancellar Department > Cellular and Molecular Research Center
Depositing User: Users 1 not found.
Date Deposited: 31 Dec 2017 05:01
Last Modified: 18 Feb 2018 09:38

Actions (login required)

View Item View Item